Agnostic (data)

DentalPlans.com Launches First-Of-Its-Kind Guided Dental Plan Finder

Retrieved on: 
Tuesday, June 27, 2023
Dental care, Cigna, Overalls, Delta Dental, Agnostic (data), Dentist, Health, Patient, Aetna, Dentistry, Health insurance, Humana, Dental

FORT LAUDERDALE, Fla. , June 27, 2023 /PRNewswire/ -- DentalPlans.com, the largest dental plan marketplace, and part of the Henry Schein One portfolio of solutions, today announced the launch of its new guided online plan finder to provide dental plan recommendations to consumers in minutes. The online plan finder is the first of its kind and size. By leveraging user responses to a short questionnaire, the plan finder will intelligently and agnostically provide personalized plan recommendations. This includes dental savings plans and/or dental insurance plans that best fit the needs of individual consumers, ensuring more people can afford to take care of their oral health.

Key Points: 
  • FORT LAUDERDALE, Fla. , June 27, 2023 /PRNewswire/ -- DentalPlans.com , the largest dental plan marketplace, and part of the Henry Schein One portfolio of solutions, today announced the launch of its new guided online plan finder to provide dental plan recommendations to consumers in minutes.
  • By leveraging user responses to a short questionnaire, the plan finder will intelligently and agnostically provide personalized plan recommendations.
  • DentalPlans.com's guided plan finder makes it simple for patients to choose the plan that is right for them.
  • Dental insurance can also reduce costs at the dentist, and there are a number of different options that may be recommended using the guided plan finder.

Amadis Extends Payments Industry Leadership with PURE Kernel Certification for SoftPos

Retrieved on: 
Monday, March 7, 2022
Finance, Banking, Professional Services, Technology, Software, Agnos, Investment, Tablet, Industry, Agnostic (data), Organization, Aircraft, Certification, Solution, Geography, Compliance, JCB, EMV, L2, Technology, COTS, PURE, Android, IOS SDK, IOT, Payment card, Mobile phone, Online shopping, Amadís de Gaula, Finance, Banking, Professional Services, Technology, Software

Amadis , a leading supplier of EMV Level 2 card processing stack and payments software solutions, today announced it has extended certification of the PURE kernel, to include L2 contactless compliance for SoftPos.

Key Points: 
  • Amadis , a leading supplier of EMV Level 2 card processing stack and payments software solutions, today announced it has extended certification of the PURE kernel, to include L2 contactless compliance for SoftPos.
  • The certification adds to Amadis library of payment kernels , the industrys most extensive by a wide margin, covering all worldwide payment network kernels deployed globally.
  • Amadis kernel library is part of its suite of software solutions running on more than 40 million PCI-PTS devices worldwide.
  • Amadis Agnos support of PURE EMV L2 specification is an extension of the Amadis vision to deliver universal payment acceptance globally.

Beam Global Announces Strategic Acquisition of AllCell Technologies, a Leader in Energy Storage Solutions

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Entrepreneurship, Government, COGS, Twitter, Growth, Phrase, Argonne National Laboratory, UAV, ARC, Fortune 500, Illinois Institute of Technology, Agnostic (data), Clean technology, Sale, Environment, Safety, EVSI, Aviation, Transport, BMS, Fortune, Architecture, Acquisition, Work, Ford Motor Company, LinkedIn, Robotics, Leadership, Beam Suntory, EV, Life, IP, SAN, Nasdaq, Lifting, YouTube, Internationalization, Forward-looking statement, EVS, AVL, Solution, Risk management, Renewable energy, Beam, Technology

Energy storage is crucial to Beam Globals value proposition and battery systems currently account for approximately 30% of Beam Global products bills of materials.

Key Points: 
  • Energy storage is crucial to Beam Globals value proposition and battery systems currently account for approximately 30% of Beam Global products bills of materials.
  • AllCell brings a team comprised of some of the energy storage industrys finest scientists, engineers and operations and manufacturing leaders.
  • In consideration for the sale of AllCell assets, the AllCell shareholders will receive 1,055,000 shares of Beam Global restricted common stock at closing.
  • AllCell Technologies is a leader in high performance energy storage solutions used in electric vehicles, micro mobility, aviation, robotics, stationary storage and maritime applications.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, General Health, Other Health, Health, Oncology, Blood, Efficiency, Explainable artificial intelligence, Non-alcoholic fatty liver disease, Saliva, Entrepreneurship, EHR, Â, Pathology, Informatics, Laboratory, Liquid biopsy, Breast cancer, Industry, Classification, Lung, NAFL, Behavior, Health, IV, NAFLD, IP, NASH, CEO, Disease, Science, Technology, Lists of diseases, Fatty liver disease, Clinical trial, Partnership, Molecular medicine, Solution, Woman, Risk, Liver, Agnostic (data), R, Ecosystem, Intellectual property, Time, LBS, Degenerative disease, Diagnosis, CLIA, Patient, Biology, Lung cancer, Research, Drug development, Data analysis, Time-invariant system, Medical imaging, Fine chemical, Medical device, IV BioHoldings, P4 Diagnostix®, Liquid Biosciences, IV BIOHOLDINGS, P4 DIAGNOSTIX®, LIQUID BIOSCIENCES

Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

Key Points: 
  • Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.
  • IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization.
  • We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.